Latest stories on KTTA
Pasithea gets FDA clearance for Phase 2 PAS-004 trial in skin neurofibromas
The Fly74 · bullishproduct/pr
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Business Insider74 · bullishproduct/pr
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
GlobeNewswire74 · bullishproduct/pr
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Business Insider52 · neutralproduct/pr
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
GlobeNewswire53 · neutralproduct/pr
Pasithea Therapeutics announces PAS-004 data at ESMO
The Fly58 · neutralproduct/pr
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
GlobeNewswire67 · bullishproduct/pr
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Business Insider64 · neutralproduct/pr
Pasithea Therapeutics Corp. (KTTAW) files 8-K
SEC 8-K50 · neutralgeneral
Pasithea Therapeutics Corp. (KTTAW) files 8-K
SEC 8-K50 · neutralgeneral
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
StockTitan56 · neutralgeneral
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
GlobeNewswire56 · neutralgeneral
Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance
TipRanks50 · neutralgeneral
Pasithea Therapeutics Corp. (KTTA) files 8-K
SEC 8-K34 · bearishgeneral
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
StockTitan56 · neutralproduct/pr
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit | KTTA Stock News
StockTitan56 · neutralproduct/pr
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial | KTTA Stock News
StockTitan56 · neutralproduct/pr
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference | KTTA Stock News
StockTitan63 · neutralproduct/pr